[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611895":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":56,"collaborators":58,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":18,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":90,"whyStopped":18,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"IPTsc","EXPERIMENTAL","DP will be administered approximately every 2 months for two years to all eligible children enrolled in primary schools serving the target areas from clusters randomized to the interventional arm.",[13],"Drug: dihydroartemisinin-piperaquine",{"label":15,"type":16,"description":17,"interventionNames":18},"No IPTsc","NO_INTERVENTION","No IPTsc (standard of care)",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","dihydroartemisinin-piperaquine","D-Artepp, is manufactured by Guilin Pharmaceutical Co Ltd, and is prequalified by the WHO and approved for use in Uganda by the National Drug Authority. Standard treatment doses of DP (once a day x 3 days) will be administered using weight-based guidelines targeting a total dose of 6.4 mg\u002Fkg dihydroartemisinin and 51.2 mg\u002Fkg of piperaquine as per manufacturer's instructions.",[9],[26],"D-Artepp",[28],{"name":29,"affiliation":5,"role":30},"Grant Dorsey, MD, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","415-310-0525","grant.dorsey@ucsf.edu",{"name":37,"role":33,"phone":38,"phoneExt":18,"email":39},"Tamara Clark, MHS","415-517-3444","tamara.clark@ucsf.edu",[41],{"facility":42,"status":18,"city":43,"state":18,"zip":18,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Infectious Diseases Research Collaboration","Kampala","Uganda","UG",{"type":47,"coordinates":48},"Point",[49,50],32.58219,0.31628,{"lat":50,"lon":49},[53],{"name":54,"role":33,"phone":18,"phoneExt":18,"email":55},"Joaniter Nankabirwa, MBChB, MSc, PhD","jnankabirwa@yahoo.co.uk",{"type":57,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[59,62,64],{"name":60,"class":61},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"name":63,"class":6},"Infectious Diseases Research Collaboration, Uganda",{"name":65,"class":66},"Ministry of Health, Uganda","OTHER_GOV","100611895","phase-4-intermittent-preventive-treatment-of-malaria-in-school-age-children-to-decrease-community-transmission-100611895",false,"NCT07246525","Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission","Cluster Randomized Trial of Intermittent Preventive Treatment of Malaria in School-age Children to Improve the Health of Students and Decrease Community Transmission","CRITICal","Inclusion Criteria:\n\n* Child currently attending the participating school.\n* Agreement of parent\u002Fguardian to provide informed consent.\n* Agreement of children aged 8-17 years to provide assent.\n\nExclusion Criteria:\n\n* Missing school on three consecutive days of the school survey.",true,"ALL","17 Years",{"count":79,"type":80},4800,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.",[86],"Malaria",[88,89,22],"intermittent preventive treatment","school children","NOT_YET_RECRUITING","2026-05-05",{"date":93,"type":94},"2026-05-07","ACTUAL",{"date":96,"type":80},"2026-08-01",{"date":98,"type":80},"2029-08-31",{"name":5,"class":6},1]